Shares of Piramal Pharma experienced a notable rise, jumping 5.5% in early trade on October 24, following the company's impressive Q2 earnings results. The drugmaker's strong financial performance in the July-September quarter highlighted a significant boost in profitability, driven by various growth initiatives across its divisions.
Piramal Pharma's robust Q2 performance fuels stock rally
Piramal Pharma's shares climbed to ₹227.29 on the NSE at 09:38 am on October 24, demonstrating the positive market sentiment surrounding the company. The impressive financial results included a 3.5-fold surge in net profit, which rose to ₹22.59 crore, compared to ₹5.02 crore in the same quarter of the previous financial year. The growth was mainly supported by higher revenues and cost optimisation, leading to margin expansion.
Growth in CDMO and Consumer Healthcare divisions
The company's Contract Development and Manufacturing Organisation (CDMO) business played a pivotal role in its Q2 performance, with a 24% year-on-year revenue growth to ₹1,320 crore. This segment, which contributes 59% to Piramal Pharma's total revenue, benefited from increased demand for innovation-driven projects. To cater to the rising need for sterile fill-finish capabilities, the company announced an $80 million expansion of its Lexington facility, with completion expected by FY27.
Meanwhile, the Consumer Healthcare (CHG) segment saw steady volume growth in inhalation anaesthesia products across the US and Emerging Markets. The India Consumer Healthcare (ICH) division also demonstrated strength as power brands and e-commerce sales continued to expand.
Revenue growth and margin expansion
Piramal Pharma reported a revenue increase of 17.3% for the September quarter, reaching ₹2,241.75 crore compared to ₹1,911.38 crore in Q2 FY24. The higher revenue, coupled with reduced operating expenses, led to a substantial improvement in margins. The company's EBITDA margin expanded by 130 basis points year-on-year, reaching 15.2% for the quarter.
Long-term outlook and growth targets
Nandini Piramal, Chairperson of Piramal Pharma, expressed optimism regarding the company's future, stating, "We continue our momentum of delivering healthy revenue growth accompanied by year-on-year EBITDA margin expansion." She attributed the improved financial performance to consistent growth in the CDMO business, particularly in innovation-related work and on-patent commercial revenues.
Looking ahead, Piramal Pharma remains committed to its long-term financial objectives, aiming for US$2 billion in revenue with a 25% EBITDA margin and a net debt/EBITDA ratio of 1x by FY30.
Market implications for share market investment
The significant stock surge following the Q2 earnings report underscores the potential of Piramal Pharma as a promising option for share market investment. With robust growth across its divisions, expansion plans, and strong financial targets, the company presents a compelling case for investors seeking exposure in the pharmaceutical sector.
Investors interested in share market investment can find value in companies like Piramal Pharma, which are leveraging innovation and expansion to drive growth. As the company pursues its ambitious long-term targets, it could further bolster its position as an attractive stock for share market investment.
Conclusion
Piramal Pharma's solid Q2 earnings performance, marked by a sharp increase in net profit and revenue, has bolstered investor confidence, leading to a 5.5% surge in its share price. The company's focus on expanding its CDMO capabilities, coupled with consistent growth in Consumer Healthcare, positions it well for continued success. For those exploring share market investment, Piramal Pharma's growth trajectory makes it a stock worth considering.
For android only